NCT03132454 2026-04-15
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
8 trialsNCT07444710 2026-04-13
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT04681105 2026-01-28
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
Phase 1 Completed
NCT04156828 2023-06-29
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
University of Washington
Phase 1 Terminated
NCT00866307 2021-04-27
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
Children's Oncology Group
Phase 1 Completed
NCT02779283 2020-05-26
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 1 Completed
NCT01722305 2019-07-22
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
Mayo Clinic
Phase 1 Completed
NCT01403415 2015-07-10
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed